8-K: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals announced a business update and its financial results for Q4 and the full year 2024, highlighting progress with soquelitinib and other clinical programs.

Summary

• Corvus Pharmaceuticals reported its Q4 and full year 2024 financial results and provided a business update on March 25, 2025.
• The company is advancing its selective ITK inhibitor, soquelitinib, across various diseases.
• Phase 1 clinical trial data for soquelitinib in atopic dermatitis is expected in May 2025.
• Initial results from the first two cohorts of the atopic dermatitis trial showed safety and efficacy with an oral agent and novel mechanism of action.
• A registration Phase 3 clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) is enrolling at multiple clinical sites.
• A Phase 2 trial in autoimmune lymphoproliferative syndrome (ALPS) has been initiated.
• The company plans to initiate a solid tumor clinical trial in the third quarter of 2025.
• As of December 31, 2024, Corvus had $52.0 million in cash, cash equivalents, and marketable securities.
• The company expects its cash to fund operations into the first quarter of 2026.
• Research and development expenses for the full year 2024 totaled $19.4 million.
• The net loss for the full year 2024 was $62.3 million.
• Angel Pharmaceuticals, Corvus' partner in China, continues to monitor patients in a Phase 1/1b clinical trial of mupadolimab in patients with relapsed non-small cell lung cancer (NSCLC).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, a solid cash position, and strategic collaborations. However, the net loss and the delay in the solid tumor trial temper the overall outlook.

Positives

• Initial results from the Phase 1 atopic dermatitis trial showed safety and efficacy for soquelitinib.
• The Phase 3 trial for soquelitinib in PTCL is enrolling patients.
• The company's cash position of $52.0 million is expected to fund operations into Q1 2026.
• The company generated $30.3 million in net proceeds from a registered direct offering.
• Early exercise of common stock warrants resulted in cash proceeds of approximately $18.6 million.

Negatives

• The company reported a net loss of $62.3 million for the full year 2024.
• The company recorded a non-cash loss of $2.3 million related to an increase in the fair value of its warrant liability during the three months ended December 31, 2024.
• The company recorded a non-cash loss of $3.2 million from Corvus equity method investment in Angel Pharmaceuticals for the full year 2024.

Risks

• The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials is uncertain.
• The accuracy of the company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials is not guaranteed.
• The results of preclinical studies and interim data from clinical trials may not be predictive of future results.
• The company's ability to enroll sufficient numbers of patients in its clinical trials is uncertain.
• The unpredictability of the regulatory process poses a risk.
• The costs of clinical trials may exceed expectations.
• The company's ability to accurately estimate the cash on hand providing funding into the first quarter of 2026 and the company's ability to raise additional capital is uncertain.

Future Outlook

Corvus expects its cash to fund operations into the first quarter of 2026 and plans to initiate a solid tumor clinical trial in the third quarter of 2025.

Management Comments

• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated, 'We continue to advance our selective ITK inhibitor, soquelitinib, in a range of diseases.'
• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated, 'Our clinical strategy is to demonstrate the value of soquelitinibs novel mechanism of action in both cancers and immune diseases, across multiple disease indications.'

Industry Context

Corvus is operating in the competitive biopharmaceutical industry, focusing on ITK inhibition as a novel approach to immunotherapy. The company's work in T cell lymphoma and atopic dermatitis addresses areas with significant unmet medical needs.

Comparison to Industry Standards

• Corvus is developing soquelitinib, an ITK inhibitor, similar to how other companies are developing kinase inhibitors for various diseases.
• The company's focus on T cell lymphoma aligns with the industry's efforts to develop targeted therapies for hematological malignancies, similar to efforts by companies like Seagen and Kite Pharma.
• The company's work in atopic dermatitis is comparable to efforts by companies like Sanofi and Regeneron, which have developed biologic therapies for this condition.
• The company's collaboration with NIAID is similar to other biotech companies partnering with government agencies to advance clinical research.

Stakeholder Impact

• Shareholders: The update provides information on the company's financial performance and clinical development programs, which could influence investment decisions.
• Employees: The progress in clinical trials and the company's financial stability could positively impact employee morale and job security.
• Patients: The development of new therapies could offer potential treatment options for various diseases.
• Partners: The update provides information on the progress of collaborations and partnerships.

Next Steps

• Presenting Phase 1 clinical trial data for soquelitinib in atopic dermatitis in May 2025.
• Continuing enrollment in the Phase 3 clinical trial of soquelitinib in PTCL.
• Advancing the Phase 2 trial in autoimmune lymphoproliferative syndrome (ALPS).
• Initiating a solid tumor clinical trial in the third quarter of 2025.
• Monitoring patients in the mupadolimab trial for relapsed NSCLC by Angel Pharmaceuticals.

Key Dates

Keywords

soquelitinib, ITK inhibitor, atopic dermatitis, peripheral T cell lymphoma, PTCL, ALPS, ciforadenant, mupadolimab, clinical trials, financial results, Corvus Pharmaceuticals